Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 17.5% on Friday . The stock traded as high as C$0.24 and last traded at C$0.24. 865,576 shares changed hands during mid-day trading, an increase of 50% from the average session volume of 576,068 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Performance
The stock has a 50-day moving average price of C$0.09 and a 200-day moving average price of C$0.07. The stock has a market cap of C$20.04 million, a P/E ratio of -11.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Using the MarketBeat Dividend Tax Calculator
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Expert Stock Trading Psychology Tips
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Conference Calls and Individual Investors
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
